MYMD - Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

• Giant pharma Merck's co-developed oral coronavirus drug with Ridgeback Biotherapeutics has raised interest in non-injected vaccine alternatives.
• The space was already occupied by Oramed, a clinical-stage biotech, whose oral vaccine is based on its POD technique, together with India's Premas Biotech COVID technology.
• This is a huge market, but also a highly competitive one due to the sheer number of biotechs involved, but the Israeli company can use previous experience in diabetes and NASH.
• Still, the fact that its shares have been adversely impacted after Merck's update shows that investors suffered from acidity when digesting the news.
• I remain bullish on this diversified stock, with market action also showing that its shares have been less battered than for established COVID biotechs.

For further details see: